APA

Fung A. T., Kumar N., Vance S. K., Slakter J. S., Klancnik J. M., Spaide R. S. & Freund K. B. (20130117). Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). : Eye (London, England).

Chicago

Fung A T, Kumar N, Vance S K, Slakter J S, Klancnik J M, Spaide R S and Freund K B. 20130117. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). : Eye (London, England).

Harvard

Fung A. T., Kumar N., Vance S. K., Slakter J. S., Klancnik J. M., Spaide R. S. and Freund K. B. (20130117). Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). : Eye (London, England).

MLA

Fung A T, Kumar N, Vance S K, Slakter J S, Klancnik J M, Spaide R S and Freund K B. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). : Eye (London, England). 20130117.